solid ep organ growth outlook
point underli growth rang
deliv strong finish clear path
investor take comfort reassur baxter solid
execut detail outlook provid manag
analysi adjust outlook non-recur factor affect
next quarter suggest underli sale growth
organ guidanc bp one-tim adjust ep
guidanc impact factor would suggest ep
growth upper teen core underli growth potenti solid
margin earn execut reinforc investor confid
track deliv long-term compound-annual-growth-rate object
reiter outperform rate rais target
solid margin execut sale bil
estim mil consensu mil sale net cog
lower sg non-op item lower share
partial off-set higher deliv upsid ep rel
bd team remain activ need reach
baxter busi develop team continu evalu opportun
inject clinic care adjac manag reiter
intent deliv compound-annual-growth-rate object without need
meantim expect continu repurchas share
valuat target price base unchang
ebitda bil previous bil risk includ key product delay
failur progress lrp goal growth margin potenti new
litig regulatori qualiti issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc global manufactur provid
diversifi healthcar suppli equip area renal
hospit product
price jan rate outperform target price analyst matt miksic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base high-growth segment grow
growth grow
 close
addit detail takeaway
renal mil mil y/i cc organ
perform led increas demand new dialysi product global
patient volum increas high singl digit partial off-set lower
hd sale japan kayuga grew msd compani expect renal
grow cc organ basi reflect continu momentum pd patient
growth partial off-set lower sale center hd relat lower sale low-
margin distribut bloodlin compani exit parti distributor agreement
acut therapi mil mil y/i cc organ
perform led improv util crrt ww basi along
increas demand multi-organ support product compani expect acut
therapi grow cc organ basi
deliveri mil mil y/i flat cc organ
compani see medic deliveri busi stabil quarter
process return demand impact product pre-hurrican level
work distributor reduc inventori level compani believ
destock larg complet expect distributor purchas close
align end user demand iv therapi tough comp
result inventori buy-in mil ahead flu season well reaction
hurrican late compani expect dd declin iv therapi
repres normal quarter face easier comp svp
compani track return demand pre-hurrican level manag continu
reinforc safeti effici svp drug reconstitut infus pump
compani continu see lengthen sale cycl driven hospit connect issu
custom delay purchas new pump overal compani gain
market share expect similar amount share gain
compani expect medic deliveri grow cc organ basi driven
stabil lvp share recaptur mini-bag acceler sigma spectrum
pump easier comp
pharmaceut mil mil y/i cc organ
growth driven sale pre-mix inject anesthesia critic care product
pharmaci compound servic help off-set lower sale brevibloc
mil cyclo mil compani expect pharmaceut
declin cc flat organ basi compani expect fda
resolut clari warn letter guidanc pharmaceut
clinic nutrit mil mil y/i cc organ
compani see clinic nutrit busi stabil quarter
process return demand impact product pre-hurrican level
compani also process drive growth recoveri market educ
reinforc suppli avail saw slight pickup market
compani expect clinic nutrit grow cc organ basi
advanc surgeri mil mil y/i cc
perform includ mil sale contribut recothrom preveleak
recothrom benefit competit suppli constraint quarter
sinc resolv compani expect advanc surgeri grow cc
organ basi
mil mil y/i cc organ
perform driven increas demand contract manufactur servic
compani expect declin lsd cc organ basi
 op margin bp estim bp y/i
sale net cog lower sg non-op item lower share
partial off-set higher deliv ep upsid gross margin
bp estim benefit oper improv
off-set one-tim manufactur cost oper margin outlook
impli bp margin expans report bp exclud one-tim
item mention
compani guid organ sale growth cc ep
guidanc organ guidanc includ bp impact mil
vs mil cyclo bp fx impact addit
organ growth expect also includ impact mil relat lower
 sale brevibloc well mil lower in-cent hd sale total
two item expect neg impact growth bp compani
expect oper margin impli bp margin
expans oper margin reflect margin impact cyclo bp
brevibloc bp fx compani expect organ sale
cc ep organ guidanc includ bp impact
 cyclo fx headwind bp largest impact lower brevibloc
sale expect realiz mil mil result
bp impact addit heighten buy pattern iv busi lower
 in-cent hd sale expect impact bp
aggreg item expect impact sale growth close bp
bp brevibloc bp iv bp hd ep includ headwind
brevibloc fx cyclo
sale
sale
sale
sale
estimate
ep
estimate
chang model
lower sale estim reflect manag guidanc
year beyond also reduc revenu estim
ep estim in-lin manag guidanc
figur chang model
target price previous base unchang ebitda
bil previous bil increas target price driven primarili
failur progress lrp goal growth margin potenti new litig
regulatori qualiti issu
charl martineau univers toronto compani mention price
